miR‑483 promotes the development of colorectal cancer by inhibiting the expression level of EI24
Wei Zhou(Broad Institute), Liu Hong(National Clinical Research Center for Digestive Diseases), Rui Zhang(Air Force Medical University), Xiaoqian Wang(Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences), Haijun Zhu(Central Hospital of Zibo), Jianjun Yang(Xijing Hospital), Wanli Yang(National Clinical Research Center for Digestive Diseases), Yiding Li(National Clinical Research Center for Digestive Diseases), Shuao Xiao(Xijing Hospital), Jing Yang(Tongji University), Lili Duan(Guizhou University), Liaoran Niu(Xijing Hospital)
Cited by 12
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming
|Nature Communications|2021|414
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
c-Myc-Mediated Epigenetic Silencing of MicroRNA-101 Contributes to Dysregulation of Multiple Pathways in Hepatocellular Carcinoma
|Hepatology|2013|163
Rapidly in Situ Forming Biodegradable Robust Hydrogels by Combining Stereocomplexation and Photopolymerization
|Journal of the American Chemical Society|2007|156